Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from the thyroid C cells producing mainly calcitonin (CTN) used as tumor marker. MTC occurs either sporadic (75%) or in a hereditary form (multiple endocrine neoplasia type 2, MEN2), due to germline mutations in the RET proto-oncogene. The discovery of an MTC in a patient has several diagnostic implications involving a specific strategy: preoperative evaluation of the tumor marker CTN and the extent of the disease, classification of MTC as sporadic or hereditary by DNA testing, and screening for associated endocrinopathies in hereditary MTC. Elevated CTN is a highly sensitive and specific tumor marker for diagnosis and follow-up of MTC. CTN is directly related to the tumor mass. In patients with nodular thyroid disease, diagnosis of MTC could be made by CTN determination as an indicator of tumor burden in conjunction with fine-needle aspiration. Patients with confirmed sporadic or hereditary MTC should have a total thyroidectomy and depending on the preoperative CTN value and the extent of disease additional dissection of the lymph nodes in the central and lateral neck compartment. In MEN 2 patients diagnosed by screening, the time of prophylactic thyroidectomy depends on RET mutation and CTN level.
Endokrinologische Gemeinschaftspraxis, Brückenstr. 21, 69120, Heidelberg, Germany. friedhelm.raue@raue-endokrinologie.de.
Friedhelm
F
Raue
Endokrinologische Gemeinschaftspraxis, Brückenstr. 21, 69120, Heidelberg, Germany.
Karin
K
Frank-Raue
D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D018278:Carcinoma, Neuroendocrine / Q000175:diagnosis* / Q000453:epidemiology* / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D003581:Cytodiagnosis; D003952:Diagnostic Imaging; D020022:Genetic Predisposition to Disease; D006801:Humans; D018813:Multiple Endocrine Neoplasia Type 2a / Q000175:diagnosis* / Q000453:epidemiology* / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D018814:Multiple Endocrine Neoplasia Type 2b / Q000175:diagnosis* / Q000453:epidemiology* / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D009367:Neoplasm Staging; D010641:Phenotype; D011237:Predictive Value of Tests; D000090063:Proto-Oncogene Mas; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000453:epidemiology* / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D013965:Thyroidectomy; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas
Calcitonin; Medullary thyroid carcinomac; Multiple endocrine neoplasia type 2; RET proto-oncogene